AU4511693A - Uracil derivatives as enzyme inhibitors - Google Patents

Uracil derivatives as enzyme inhibitors

Info

Publication number
AU4511693A
AU4511693A AU45116/93A AU4511693A AU4511693A AU 4511693 A AU4511693 A AU 4511693A AU 45116/93 A AU45116/93 A AU 45116/93A AU 4511693 A AU4511693 A AU 4511693A AU 4511693 A AU4511693 A AU 4511693A
Authority
AU
Australia
Prior art keywords
compound
formula
uracil
methyl
mmoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45116/93A
Other languages
English (en)
Inventor
David Patrick Baccanari
James Leroy Kelley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU4511693A publication Critical patent/AU4511693A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU45116/93A 1992-07-10 1993-07-09 Uracil derivatives as enzyme inhibitors Abandoned AU4511693A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9214720 1992-07-10
GB929214720A GB9214720D0 (en) 1992-07-10 1992-07-10 Enzyme inhibitors
PCT/GB1993/001443 WO1994001414A1 (en) 1992-07-10 1993-07-09 Uracil derivatives as enzyme inhibitors

Publications (1)

Publication Number Publication Date
AU4511693A true AU4511693A (en) 1994-01-31

Family

ID=10718537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45116/93A Abandoned AU4511693A (en) 1992-07-10 1993-07-09 Uracil derivatives as enzyme inhibitors

Country Status (9)

Country Link
EP (1) EP0649413A1 (ja)
JP (1) JPH07508983A (ja)
AU (1) AU4511693A (ja)
CA (1) CA2139836A1 (ja)
GB (1) GB9214720D0 (ja)
IL (1) IL106290A0 (ja)
MX (1) MX9304152A (ja)
WO (1) WO1994001414A1 (ja)
ZA (1) ZA934970B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7605286B2 (en) 2003-08-06 2009-10-20 Sumitomo Chemical Company, Limited Hydroxy-protecting reagent and method of protecting hydroxy with the same
BRPI0615046C1 (pt) 2005-08-22 2021-05-25 Melior Discovery Inc uso de um composto
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
RU2427373C1 (ru) 2010-11-08 2011-08-27 Виктор Вениаминович Тец Средство для индукции эндогенного интерферона
EP3609500A4 (en) 2017-04-10 2020-08-19 Melior Pharmaceuticals I, Inc. ADIPOCYTE TREATMENT

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
JPS63290867A (ja) * 1987-05-22 1988-11-28 Sds Biotech Kk ウラシル系化合物及び殺菌剤
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
DE69126469T2 (de) * 1990-03-29 1998-01-29 Mitsubishi Chem Corp Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives

Also Published As

Publication number Publication date
WO1994001414A1 (en) 1994-01-20
JPH07508983A (ja) 1995-10-05
IL106290A0 (en) 1993-11-15
EP0649413A1 (en) 1995-04-26
GB9214720D0 (en) 1992-08-19
MX9304152A (es) 1994-04-29
CA2139836A1 (en) 1994-01-20
ZA934970B (en) 1995-01-09

Similar Documents

Publication Publication Date Title
CA2147893C (en) Enantiomerically pure .beta.-d-dioxolane nucleosides with selective anti-hepatitis .beta. virus activity
AU615681B2 (en) Nucleoside derivatives useful in treating retroviral infections
KR100225986B1 (ko) 항바이러스성 누클레오시드 배합제
US5952500A (en) Nucleoside derivatives
CA1062257A (en) Purine compounds and salts thereof
JP2900064B2 (ja) ヌクレオシド アナローグ類
JPH0378370B2 (ja)
US5376644A (en) Treatment of adenovical infections with 3'-fluoro-5-halo uracil compounds
CA2065279A1 (en) Antiviral pyrimidine nucleosides
JP2683297B2 (ja) ピリミジンアシクロヌクレオシド誘導体
AU4511693A (en) Uracil derivatives as enzyme inhibitors
CZ288515B6 (cs) Farmaceutická kombinace nebo kit obsahující inaktivátory uracilreduktázy
EP0361831B1 (en) Antiviral nucleoside combination
EP0912526A1 (en) Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
US4060616A (en) Purine derivatives with repeating unit
US20070191373A1 (en) Heterocyclic compounds for use in the treatment of viral infections
EP0539442A1 (en) Enzyme inactivators
JP3072600B2 (ja) 新規化合物、その製法及びそれを含む医薬組成物
JPH013185A (ja) 活性化合物、その製法及びそれを含む医薬組成物
US5126347A (en) Isomeric dideoxynuclesides
IE81107B1 (en) Antiviral highly water soluble stable crystalline salts of 2',3'-dideoxyinosine monohydrate 2',3'-dideoxy-2',3'-didehydrothymidine monohydrate and 2',3'-dideoxy-2'-fluoroinosine hemihydrate
US5252575A (en) Antiviral purine derivatives with improved gastrointestinal absorption
JP2020164521A (ja) 抗ウィルス薬
JPH05178746A (ja) 抗ウイルス剤
JPH06199812A (ja) 新規シクロペンテン誘導体